PubMed · 1989 · 37 citations · 0 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaOncogenesHepatic PathologyHepatocellular CarcinomaLiver CancerLiver DiseaseMyc Family OncogenesRas Family OncogenesHepatocellular Carcinoma PathogenesisImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingMyc OncogenesOncogenic Myc SignalingOncogenic Ras Mutations
An immunohistochemical assay was used to assess expression of ras p21 and myc p62 oncogene products in human hepatocellular carcinoma (HCC) and non-neoplastic liver tissues. The monoclonal antibodies Y13 259 and Myc1-9E10, specific for ras p21 and myc p62 oncoproteins, were employed on paraffin-embedded sections. Most HCCs showed enhanced ras p21 and myc p62 expression, as indicated by staining intensity. Cirrhotic livers revealed increased myc p62 and occasionally increased ras p21 expression. HBsAg+ hepatocytes showed intense immunostaining for ras p21. Fibrotic, cholestatic, fetal and normal adult liver did not present enhancement of oncoprotein production. We suggest that combined over-expression of ras and myc oncoproteins may be important for the malignant phenotypic alteration in human HCC.